HC Wainwright Has Bullish Forecast for INO FY2024 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Research analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Inovio Pharmaceuticals in a report released on Monday, January 13th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($4.19) per share for the year, up from their prior forecast of ($4.39). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.41) EPS.

INO has been the subject of several other research reports. Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Finally, Royal Bank of Canada dropped their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.40.

Inovio Pharmaceuticals Price Performance

INO opened at $1.87 on Wednesday. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The firm has a market capitalization of $48.81 million, a P/E ratio of -0.90 and a beta of 0.84. The company’s 50-day moving average is $3.27 and its 200 day moving average is $6.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of INO. Geode Capital Management LLC raised its holdings in shares of Inovio Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 38,833 shares during the period. State Street Corp increased its position in Inovio Pharmaceuticals by 11.7% in the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after buying an additional 51,414 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at $661,000. Dimensional Fund Advisors LP bought a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at $605,000. Finally, Wellington Management Group LLP purchased a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $379,000. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.